Self-assembly of lithographically patterned nanoparticles.

The construction of three-dimensional (3D) objects, with any desired surface patterns, is both critical to and easily achieved in macroscale science and engineering. However, on the nanoscale, 3D fabrication is limited to particles with only very limited surface patterning. Here, we demonstrate a self-assembly strategy that harnesses the strengths of well-established 2D nanoscale patterning techniques and additionally enables the construction of stable 3D polyhedral nanoparticles. As a proof of the concept, we self-assembled cubic particles with sizes as small as 100 nm and with specific and lithographically defined surface patterns.

[1]  I. Soubeyran,et al.  KRAS and BRAF Mutational Status in Primary Colorectal Tumors and Related Metastatic Sites: Biological and Clinical Implications , 2010, Annals of Surgical Oncology.

[2]  Linda Mol,et al.  Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. , 2009, The New England journal of medicine.

[3]  J. Meyerhardt,et al.  KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803 , 2009, Clinical Cancer Research.

[4]  Y. Bang,et al.  Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells , 2009, Molecular Cancer Therapeutics.

[5]  J. Tabernero,et al.  10LBA Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial , 2009 .

[6]  M. Karamouzis,et al.  Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors. , 2009, The Lancet. Oncology.

[7]  W. Sellers,et al.  PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. , 2009, Cancer research.

[8]  K. Patterson,et al.  Dual-specificity phosphatases: critical regulators with diverse cellular targets. , 2009, The Biochemical journal.

[9]  S. Baker,et al.  PTEN and the PI3-kinase pathway in cancer. , 2009, Annual review of pathology.

[10]  J. D. Benson,et al.  Single-vector inducible lentiviral RNAi system for oncology target validation , 2009, Cell cycle.

[11]  Ralph Weissleder,et al.  Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers , 2008, Nature Medicine.

[12]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[13]  P. Marynen,et al.  DUSP4 expression level in colorectal primaries predicts overall survival benefit in Kras wild-type and Kras mutant colorectal cancer after treatment with cetuximab for metastatic disease , 2008 .

[14]  J. Hauser,et al.  Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor. , 2008, Cancer research.

[15]  K. Shokat,et al.  PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. , 2008, Cancer research.

[16]  Alice T. Loo,et al.  PTEN-deficient cancers depend on PIK3CB , 2008, Proceedings of the National Academy of Sciences.

[17]  W. Gerald,et al.  Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. , 2008, The Journal of clinical investigation.

[18]  J. Sebolt-Leopold,et al.  Advances in the Development of Cancer Therapeutics Directed against the RAS-Mitogen-Activated Protein Kinase Pathway , 2008, Clinical Cancer Research.

[19]  Daniel J. Freeman,et al.  Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. , 2008, Clinical colorectal cancer.

[20]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  C. Mao,et al.  Hierarchical self-assembly of DNA into symmetric supramolecular polyhedra , 2008, Nature.

[22]  A. Lièvre,et al.  KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Pitera,et al.  Soft patchy nanoparticles from solution-phase self-assembly of binary diblock copolymers. , 2008, Nano letters.

[24]  N. Saxena,et al.  RAS: Target for Cancer Therapy , 2008, Cancer investigation.

[25]  Dongsheng Tu,et al.  Cetuximab for the treatment of colorectal cancer. , 2007, The New England journal of medicine.

[26]  D. Gracias,et al.  Surface tension-driven self-folding polyhedra. , 2007, Langmuir : the ACS journal of surfaces and colloids.

[27]  F. Blanchard,et al.  Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy , 2007, British Journal of Cancer.

[28]  L. Cantley,et al.  Ras, PI(3)K and mTOR signalling controls tumour cell growth , 2006, Nature.

[29]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[30]  H. J. Lezec,et al.  The optical response of nanostructured surfaces and the composite diffracted evanescent wave model , 2006 .

[31]  Tak W. Mak,et al.  Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis , 2006, Nature Reviews Cancer.

[32]  Gordon B Mills,et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.

[33]  Todd R. Golub,et al.  BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.

[34]  J. Ptak,et al.  Colorectal cancer: Mutations in a signalling pathway , 2005, Nature.

[35]  C. Mirkin,et al.  On-Wire Lithography , 2005, Science.

[36]  Carlo Rago,et al.  Mutant PIK3CA promotes cell growth and invasion of human cancer cells. , 2005, Cancer cell.

[37]  Silvia Benvenuti,et al.  Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. , 2005, The Lancet. Oncology.

[38]  D. Hedley,et al.  Raf kinase as a target for anticancer therapeutics , 2005, Molecular Cancer Therapeutics.

[39]  J. Sebolt-Leopold,et al.  Targeting the mitogen-activated protein kinase cascade to treat cancer , 2004, Nature Reviews Cancer.

[40]  J. Hecht,et al.  Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  S. Glotzer,et al.  Self-Assembly of Patchy Particles. , 2004, Nano letters.

[42]  E. Van Cutsem,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[43]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[44]  Francesco Stellacci,et al.  Spontaneous assembly of subnanometre-ordered domains in the ligand shell of monolayer-protected nanoparticles , 2004, Nature materials.

[45]  E. Van Cutsem,et al.  Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Neal J Meropol,et al.  Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  George M. Whitesides,et al.  Surface tension-powered self-assembly of microstructures - the state-of-the-art , 2003 .

[48]  D. Polsky,et al.  Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. , 2003, Cancer research.

[49]  L. Ellis,et al.  Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[51]  G. Whitesides,et al.  Self-Assembly at All Scales , 2002, Science.

[52]  C. Wilkinson,et al.  Substratum nanotopography and the adhesion of biological cells. Are symmetry or regularity of nanotopography important? , 2001, Biophysical chemistry.

[53]  Y. Yarden.  The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. , 2001, European journal of cancer.

[54]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[55]  M. Škarabot,et al.  Mechanism of liquid crystal alignment on submicron patterned surfaces , 2001 .

[56]  Tien,et al.  Forming electrical networks in three dimensions by self-assembly , 2000, Science.

[57]  Song Xu,et al.  Nanofabrication of self-assembled monolayers using scanning probe lithography. , 2000, Accounts of chemical research.

[58]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[59]  H. Fuchs,et al.  Nanoscopic channel lattices with controlled anisotropic wetting , 2000, Nature.

[60]  T. Roberts,et al.  Tangled Webs: Evidence of Cross-Talk Between c-Raf-1 and Akt , 1999, Science's STKE.

[61]  Takashi Tsuruo,et al.  Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors , 1999, Oncogene.

[62]  Harold G. Craighead,et al.  Cell attachment on silicon nanostructures , 1997 .

[63]  M. Wigler,et al.  P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[64]  George M. Whitesides,et al.  Three-dimensional self-assembly of millimetre-scale components , 1997, Nature.

[65]  S. Chou,et al.  Imprint Lithography with 25-Nanometer Resolution , 1996, Science.

[66]  Michael J. Fry,et al.  Phosphatidylinositol-3-OH kinase direct target of Ras , 1994, Nature.

[67]  S. Shirasawa,et al.  Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. , 1993, Science.

[68]  Joyce Bos.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[69]  C. Wilkinson,et al.  Sub‐20‐nm‐wide metal lines by electron‐beam exposure of thin poly(methyl methacrylate) films and liftoff , 1981 .

[70]  C. J. Mogab,et al.  Plasma etching of Si and SiO2—The effect of oxygen additions to CF4 plasmas , 1978 .

[71]  G. Mills,et al.  Improved classification of breast cancer by analysis of genetic alterations and gene expression profiling , 2011 .

[72]  H. Hurwitz,et al.  The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. , 2009, The oncologist.

[73]  J. Downward.  Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.

[74]  R. Muschel,et al.  Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. , 2003, Cancer research.